PMID- 23907002
OWN - NLM
STAT- MEDLINE
DCOM- 20140120
LR  - 20220321
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 49
IP  - 17
DP  - 2013 Nov
TI  - Treatment of children over the age of one year with unresectable localised 
      neuroblastoma without MYCN amplification: results of the SIOPEN study.
PG  - 3671-9
LID - S0959-8049(13)00546-7 [pii]
LID - 10.1016/j.ejca.2013.07.002 [doi]
AB  - BACKGROUND: In children older than 1 year with localised unresectable 
      neuroblastoma (NB), treatment strategies are heterogeneous according to the 
      national groups. The objective of this phase III non-randomised study was to 
      evaluate the efficacy of conventional chemotherapy followed by surgery. PATIENTS 
      AND METHODS: In the presence of surgical risk factors (SRF), six courses of 
      chemotherapy alternating Carboplatin-Etoposide and 
      Vincristin-Cyclophosphamide-Doxorubicin were given, and surgical resection was 
      attempted after four. Survival analyses were performed using an 
      intention-to-treat approach. The main objective was to achieve a 5-year survival 
      over 80%. RESULTS: Out of 191 registered children, 160 were evaluable. There were 
      62.5% older than 18 months and 52.5% had unfavourable histology according to 
      International Neuroblastoma Pathology Classification (INPC). Chemotherapy reduced 
      the number of SRFs by one third. Delayed surgery was attempted in 86.3% of 
      patients and was complete or nearly complete in 74%. The 5-year EFS and OS were 
      76.4% and 87.6% respectively, with significant better results for patients 
      younger than 18 months or with favourable histology. CONCLUSION: This strategy 
      provides encouraging results in children older than 1 year or 12 months with 
      localised unresectable NB without MYCN amplification. However, in children older 
      than 18 months and with unfavourable histology, additional treatment is 
      recommended.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Kohler, J A
AU  - Kohler JA
AD  - Department of Paediatric Oncology, Southampton General Hospital, Southampton, UK.
FAU - Rubie, H
AU  - Rubie H
FAU - Castel, V
AU  - Castel V
FAU - Beiske, K
AU  - Beiske K
FAU - Holmes, K
AU  - Holmes K
FAU - Gambini, C
AU  - Gambini C
FAU - Casale, F
AU  - Casale F
FAU - Munzer, C
AU  - Munzer C
FAU - Erminio, G
AU  - Erminio G
FAU - Parodi, S
AU  - Parodi S
FAU - Navarro, S
AU  - Navarro S
FAU - Marquez, C
AU  - Marquez C
FAU - Peuchmaur, M
AU  - Peuchmaur M
FAU - Cullinane, C
AU  - Cullinane C
FAU - Brock, P
AU  - Brock P
FAU - Valteau-Couanet, D
AU  - Valteau-Couanet D
FAU - Garaventa, A
AU  - Garaventa A
FAU - Haupt, R
AU  - Haupt R
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130729
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Etoposide/administration & dosage
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Infant
MH  - Male
MH  - N-Myc Proto-Oncogene Protein
MH  - Neuroblastoma/*drug therapy/genetics/mortality
MH  - Nuclear Proteins/*genetics
MH  - Oncogene Proteins/*genetics
MH  - Survival Analysis
MH  - Vincristine/administration & dosage
OTO - NOTNLM
OT  - Children
OT  - Conventional chemotherapy
OT  - Localised neuroblastoma
OT  - Unresectable
EDAT- 2013/08/03 06:00
MHDA- 2014/01/21 06:00
CRDT- 2013/08/03 06:00
PHST- 2013/01/18 00:00 [received]
PHST- 2013/06/06 00:00 [revised]
PHST- 2013/07/01 00:00 [accepted]
PHST- 2013/08/03 06:00 [entrez]
PHST- 2013/08/03 06:00 [pubmed]
PHST- 2014/01/21 06:00 [medline]
AID - S0959-8049(13)00546-7 [pii]
AID - 10.1016/j.ejca.2013.07.002 [doi]
PST - ppublish
SO  - Eur J Cancer. 2013 Nov;49(17):3671-9. doi: 10.1016/j.ejca.2013.07.002. Epub 2013 
      Jul 29.